Clinical Trial Update: A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 substudy of pembrolizumab (MK-3475) and other investigational PD-1/PD-L1 agents in PD-1/PD-L1 refractory urothe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Urothelial Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING